Bioanalysis of Therapeutic Oligonucleotides Using Hybridization-Based Immunoassay Techniques

Handbook of Analysis of Oligonucleotides and Related Products

Volumn , Issue , 2011, Pages 265-283

  Legakis, Helen ^a   Carriero, Sandra ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872465454     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b10714-13     Document Type: Chapter

References (64)

1. Crooke, S. T. 2004. Progress in antisense technology. Annual Review of Medicine 55: 61-95.
2. Malik, R., and I. Roy. 2008. Design and development of antisense drugs. Expert Opinion on Drug Discovery 3(10): 1189-1207.
3. Pappas, T. C., A. G. Bader, B. F. Andruss, D. Brown, and L. P. Ford. 2008. Applying small RNA mol-ecules to the directed treatment of human diseases: realizing the potential. Expert Opinion on Therapeutic Targets 12(1): 115-127.
4. Carthew, R. W., and E. J. Sontheimer. 2009. Origins and mechanisms of miRNAs and siRNAs. Cell 136(4): 642-655.
5. Castanotto, D., and J. J. Rossi. 2009. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457(7228): 426-133.
6. Dorn, A., and S. Kippenberger. 2008. Clinical application of CpG-, non-CpG- and antisense oligodeoxy-nucleotides as immunomodulators. Current Opinion in Molecular Therapeutics 10(1): 10-20.
7. Kaur, G., and I. Roy. 2008. Therapeutic application of aptamers. Expert Opinion on Investigational New Drugs 17(1): 47-60.
8. Morishita, R., G. H. Gibbons, M. Horiuchi, K. E. Ellison, M. Nakama, L. Zhang, Y. Kaneda, T. Ogihara, and V. J. Dzau. 1995. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proceedings of the National Academy of Sciences of the United States of America 92(13): 5855-5859.
9. Sel, S., W. Henke, A. Dietrich, U. Herz, and H. Renz. 2006. Treatment of allergic asthma by target-ing transcription factors using nucleic-acid based technologies. Current Pharmaceutical Design 12(25): 3291-3304.
10. Usman, N., and L. M. Blarr. 2000. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. Journal of Clinical Investigation 106(10): 1197-1202.
11. Isaka, Y. 2007. DNAzymes as potential therapeutic molecules. Current Opinion in Molecular Therapeutics 9(2): 132-136.
12. Behlke, M. A. 2008. Chemical modification of siRNAs for in vivo use. Oligonucleotides 18(4): 305-320.
13. Urban, E., and C. R. Noe. 2003. Structural modifications of antisense oligonucleotides. Farmaco 58: 243-258
14. Faria, M., and H. Ulrich. 2008. Sugar boost: when ribose modifications improve oligonucleotide per-formance Current Opinion in Molecular Therapeutics 10: 168-175
15. Prakash, T. P., and B. Bhat. 2007. 2'-Modified oligonucleotides for antisense therapeutics. Current Topics in Medicinal Chemistry 7: 641-649
16. Abes, R, A A Arzumanov, H M Moulton, S Abes, G D Ivanova, P L Iversen, M J Gait, and B Lebleu. 2007. Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochemical Society Transactions 35(4): 775-779
17. Zhao, X., F. Pan, C. M. Holt, A. L. Lewis, and J. R. Lu. 2009. Controlled delivery of antisense oligonucleo-tides: a brief review of current strategies Expert Opinion on Drug Delivery 6(7): 673-686
18. Cossum, P A, H Sasmor, D Dellinger, L Truong, L Cummins, S R Owens, P M Markham, J P Shea, and S. Crooke. 1993. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats Journal of Pharmacology and Experimental Therapeutics 267(3): 1181-1190.
19. Leeds, J. M., M. J. Graham, L. Truong, and L. L. Cummins. 1996. Quantitation of phosphorothioate oligonucleotides in plasma. Analytical Biochemistry 235(1): 36-13.
20. Chen, S H, and J M Gallo 1998 Use of capillary electrophoresis methods to characterize the pharma-cokinetics of antisense drugs Electrophoresis 19: 2861-2869
21. Reyderman, L., and S. Stavchansky. 1996. Determination of single-stranded oligodeoxynucleotides by capillary gel electrophoresis with laser-induced fluorescence and on column derivatization. Journal of Chromatography A 755(2): 271-280.
22. Willems, A V, D L Deforce, C H Van Peteghem, and J F Van Bocxlaer 2005 Analysis of nucleic acid constituents by on-line capillary electrophoresis-mass spectrometry Electrophoresis 26(7-8): 1221-1253.
23. Bigelow, J. C., L. R. Chrin, L. A. Mathews, and J. J. McCormack. 1990. High-performance liquid chro-matographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids. Journal of Chromatography B: Biomedical Sciences and Applications 533: 133-140.
24. Chen, S. H., M. Qian, J. M. Brennan, and J. M. Gallo. 1997. Determination of antisense phophorothio-ate oligonucloetides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis. Journal of Chromatography B: Biomedical Sciences and Applications 692(1): 43-51
25. Arora, V., D. C. Knapp, M. T. Reddy, D. D. Weller, and P. L. Iversen. 2003. Bioavailability and efficacy of 2. antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. Journal of Pharmaceutical Sciences 91(4): 1009-1018.
26. Huber, C G, and H Oberacher 2001 Analysis of nucleic acids by on-line liquid chromatography-mass spectrometry. Mass Spectrometry Reviews 20(5): 310-343.
27. Lin, Z J, W Li, and G Dai 2007 Application of LC-MS for quantitative analysis and metabolite identification of therapeutic oligonucleotides. Journal of Pharmaceutical and Biomedical Analysis 44(2): 330-341
28. Zhang, G., J. Lin, K. Srinivasan, O. Kavetskaia, and J. N. Duncan. 2007. Strategies for bioanalysis of an oligonucleotide class macromolecule from rat plasma using liquid chromatography-tandem mass spec-trometry. Analytical Chemistry 79(9): 3416-3424.
29. Yu, R Z, K M Lemonidis, M J Graham, J E Matson, R M Crook, D L Tribble, M K Wedel, A A Levin, and R S Geary 2009 Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100 Biochemical Pharmacology 77(5): 910-919.
30. Leaman, D W 2008 Recent progress in oligonucleotide therapeutics: antisense to aptamers Expert Opinion on Drug Discovery 3(9): 997-1009
31. Schwarz, D. Z., G. Hutvagner, T. Du, Z. Xu, N. Aronin, and P. D. Zamore. 2003. Asymmetry in the assembly of the RNAi enzyme complex Cell 115(2): 199-208
32. Green, N. M. 1990. Avidin and streptavidin. Methods in Enzymology 184: 51-67.
33. Meng, Y, K High, J Antonello, M W Washabaugh, and Q Zhao Enhanced sensitivity and precision in an enzyme-linked immunosorbent assay with fluorogenic substrates compared with commonly used chromogenic substrates. Analytical Biochemistry 345: 227-236.
34. Blackburn, M. G., and M. J. Gait. 1996. Nucleic Acids in Chemistry and Biology. New York: Oxford University Press
35. Braasch, D. A., and D. R. Corey. 2001. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA Chemistry and Biology 8(1): 1-7
36. You, Y., B. G. Moreira, M. A. Behlke, and R. Owczarzy. 2006. Design of LNA probes that improve mis-match discrimination Nucleic Acids Research 34(8): e60
37. Butch, A W 2000 Dilution protocols for detection of hook effects/prozone phenomenon Clinical Chemistry 46(10): 1719-1720.
38. Yu, R Z, B Baker, A Chappell, R S Geary, E Cheung, and A A Levin 2002 Development of an ultra-sensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Analytical Biochemistry 301(1): 19-25.
39. Baker, B. F., Z. Yu, and J. M. Leed. 2000. Method for quantitating oligonucleotides. U. S. Patent 6, 355, 438. Isis Pharmaceuticals Inc
40. Eder, P. S., R. J. Devine, J. M. Dagle, and J. A. Walder. 1991. Substrate specificity and kinetics of degra-dation of antisense oligonucleotides by a 3 '-exonuclease in plasma. Antisense Research and Development 1(2): 141-151.
41. Wojcik, M., M. Cieslak, W. J. Stec, J. W. Goding, and M. Koziolkiewicz. 2007. Nucleotide pyrophos-phatase/phosphodiesterase 1 is responsible for degradation of antisense phosphorothioate oligonucleo-tides Oligonucleotides 17(1): 134-145
42. Gamper, H B, M W Reed, T Cox, J S Virosco, A D Adams, A A Gall, J K Scholler, and R B Meyer, Jr. 1993. Facile preparation of nuclease resistant 3' modified oligodeoxynucleotides. Nucleic Acids Research 21: 145-150.
43. Yu, D., E. R. Kandimalla, L. Bhagat, J. Y. Tang, Y. Cong, J. Tang, and S. Agrawal. 2002. ‘Immunomers’-novel 3'-3'- linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents Nucleic Acids Research 30(20): 4460-4469
44. Goffin, C., V. Bailly, and W. G. Verly. 1987. Nicks 3' or 5' to AP sites or to mis-paired bases, and one-nucleotide gaps can be sealed by T4 DNA ligase. Nucleic Acids Research 15(21): 8755-8771.
45. Tolstrup, N., P. S. Neilson, J. G. Kolberg, A. M. Frankel, H. Vissing, and S. Kauppinen. 2003. OligoDesign: optimal design of LNA (locked nucleic acid) oligonucleotide capture probes for gene expression profiling Nucleic Acids Research 31(13): 3758-3762
46. Yu, Z, B F Baker, and H Wu 2003 Nuclease-based method for detecting and quantifying oligonucle-otides. WO/2002/059137. Isis Pharmaceuticals Inc.
47. Desai, N. A., and V. Shankar. 2003. Single-strand-specific nucleases. FEMS Microbiology Reviews 26(5): 457-491
48. Shenk, T E, C Rhodes, P W J Rigby, and P Berg 1975 Biochemical method for mapping mutational alterations in DNA with S1 nuclease: the location of deletions and temperature-sensitive mutations in simian virus 40 Proceedings on the National Academy of Sciences 72(3): 989-993
49. Wei, X., G. Dai, G. Marcucci, Z. Liu, D. Hoyt, W. Blum, and K. K. Chan. 2006. A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices. Pharmaceutical Research 23(6): 1251-1264.
50. Efler, S. M., L. Zhang, B. O. Noll, E. Uhlmann, and H. L. Davis. 2005. Quantitation of oligonucleotides in human plasma with a novel hybridization assay offers greatly enhanced sensitivity over capillary gel electrophoresis. Oligonucleotides 15: 119-131.
51. Tolstrup, N, P S Neilson, J G Kolberg, A M Frankel, H Vissing, and S Kauppinen 2003 OligoDesign: optimal design of LNA (locked nucleic acid) oligonucleotide capture probes for gene expression profiling Nucleic Acids Research 31(13): 3758-3762
52. Deverre, J. R., V. Boutet, E. Ezan, J. Grassi, and J. M. Grognet. 1997. A competitive enzyme hybridiza-tion assay for plasma determination of phosphodiester and phosphorothioate antisense oligonucleotides Nucleic Acids Research 25(18): 3584-3589.
53. Gottschalk, P. G., and J. R. Dunn. 2005. The five-parameter logistic: A characterization and comparison with the four-parameter logistic Analytical Biochemistry 343: 54-65
54. Crooke, S T 2008 Antisense Drug Technology Principles, Strategies, and Applications New York: CRC Press
55. Pitts, R. F., W. D. Lotspeich, W. A. Schiess, J. L. Ayer, and P. Miner. 1948. The renal regulation of acid base balance in man I The nature of the mechanism for acidifying the urine Journal of Clinical Investigation 27(1): 48-56.
56. De Fougerolles, A. R. 2008. Delivery vehicles for small interfering RNA in vivo. Human Gene Therapy 19: 125-132.
57. Whitehead, K A, R Langer, and D G Anderson 2009 Knocking down barriers: advances in siRNA delivery Nature Reviews 8: 129-138
58. Perreault, D. M., and E. V. Anslyn. 1997. Unifying the current data on the mechanism of cleavage-transesterification of RNA. Angewandte Chemie (International Edition in English) 36: 432-450.
59. U S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). 2001. Guidance for Industry: Bioanalytical Method Validation
60. Kelley, M., and B. DeSilva. 2007. Key elements of bioanalytical method validation for macromolecules. AAPS Journal 9(2): E156-E163.
61. Rocci, M. L., Jr., V. Devanarayan, D. B. Haughley, and P. Jardieu. 2007. Confirmatory reanalysis of incurred bioanalytical samples AAPS Journal 9(3): E336-E343
62. Tremblay, G. A., P. R. Oldfield, and A. J. Bartlett. 2009. A parent-specific hybridization assay for quan-tifying therapeutic oligonucleotides and siRNA in biological samples Poster. Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists (AAPS), Los Angeles, California, Nov. 8-12 (Patent Pending No. US 61/258, 046).
63. Nolan, J. P., and F. Mandy. 2006. Multiplexed and Microparticle-based Analyses: Quantitative Tools for the Large-Scale Analysis of Biological Systems. Cytometry 69(5): 318-325.
64. Gugliermo-Viret, V, and P Thullier 2007 Comparison of an electrochemiluminescence assay in plate format over a colorimetric ELISA, for the detection of ricin B chain (RCA-B). Journal of Immunological Methods 328: 70-78